文献速递头颈外科

选择性颈清扫在上颌窦鳞状细胞癌治疗中的作用

The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma.
PubMed 文献 · Laryngoscope · 2017-11-29

基于SEER数据库2004至2013年927例临床N0M0上颌窦鳞状细胞癌患者的回顾性分析显示,选择性颈清扫(END)总体显著降低5年死亡风险(HR=0.646,95%CI 0.419-0.873,P=0.047),对T3期患者获益显著(HR=0.471,95%CI 0.261-0.680,P=0.001),对T1/T2及T4期未显示独立生存获益。

要点

  • END总体显著降低N0M0上颌窦鳞癌5年死亡风险(HR=0.646)。
  • T3期患者接受END显著降低5年死亡风险(HR=0.471)。
  • T1/T2及T4期患者END未显示独立生存获益。

核心结论

  • END改善肿瘤大小>4cm及晚期T分期(AJCC TIII)上颌窦鳞癌患者的疾病特异性生存。
  • 建议对上颌窦鳞癌>4cm且晚期患者行上颌骨切除术时考虑同期行END。

研究设计与样本

  • 基于人群的回顾性数据库分析,数据来自SEER数据库。
  • 纳入2004至2013年诊断为N0M0上颌窦鳞状细胞癌患者共927例。
  • 采用频率函数、Kaplan-Meier及Cox回归模型分析人口学、治疗状态和生存结局。

主要发现

  • 总体队列中END显著且独立降低5年死亡风险(HR=0.646,95%CI 0.419-0.873,P=0.047)。
  • T1/T2及T4期肿瘤中END未独立改善5年生存。
  • T3期疾病中END显著降低5年死亡风险(HR=0.471,95%CI 0.261-0.680,P=0.001),不受其他协变量包括辅助放疗影响。
  • 自SEER开始收集该数据以来,伴随END的上颌窦鳞癌手术比例增加,但未显示显著性(R2=0.622)。

关键数值与推荐

  • END总体降低5年死亡风险:HR=0.646,95%CI 0.419-0.873,P=0.047。
  • T3期END降低5年死亡风险:HR=0.471,95%CI 0.261-0.680,P=0.001。
  • 证据等级:4级。

临床怎么用

  • 上颌骨切除术治疗上颌窦鳞癌时,对肿瘤>4cm及晚期T分期(AJCC TIII)患者可考虑同期行END。
  • T1/T2及T4期患者END的生存获益未获独立证实,决策需个体化。

局限性

  • 回顾性数据库分析,证据等级为4级。
  • END比例增加趋势未达统计学显著性(R2=0.622)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study is designed to analyze the survival benefits of elective neck dissection (END) in the treatment of squamous cell carcinoma of the maxillary sinus (MS-SCC) with clinically negative neck lymph nodes (N0) and no metastasis (M0). STUDY DESIGN: The aim of this study was to evaluate whether END improves survival in patients with MS-SCC. METHODS: This study is a population-based, concurrent retrospective database analysis of patients diagnosed with N0M0 MS-SCC from 2004 to 2013. Data were acquired from the Surveillance, Epidemiology, and End Results database. Frequency functions, Kaplan-Meier and Cox regression models were queried to analyze demographics, treatment status, and survival outcomes. RESULTS: There were a total of 927 MS-SCC cases in the database between 2004 and 2013. This analysis revealed that for the overall cohort, END significantly and independently reduces the 5-year hazard of death in MS-SCC (hazard ratio [HR] = 0.646, 95% confidence interval [CI] = 0.419-0.873, P = 0.047). For early tumor (T)1/T2 tumors and T4 tumors, END did not independently improve 5-year survival. However, for T3 disease, END significantly reduced the 5-year hazard of death in MS-SCC (HR = 0.471, 95% CI = 0.261-0.680, P = 0.001), regardless of other covariates, including adjuvant radiation. There has been an increase in the percentage of MS-SCC surgeries that have been accompanied by END since SEER started collecting this data, although this did not demonstrate significance (R2 = 0.622). CONCLUSION: END improves disease-specific survival in patients with MS-SCC size > 4 cm and advanced T-stage (American Joint Committee on Cancer AJCC TIII). Therefore, surgeons performing maxillectomies should consider conducting an END concurrent with maxillectomy for those with size > 4 cm advanced stage cancer. LEVEL OF EVIDENCE: 4. Laryngoscope, 1835-1841, 2018.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Sangal NR, Lee YJ, Brady JS, et al. The role of elective neck dissection in the treatment of maxillary sinus squamous cell carcinoma. Laryngoscope. 2017. PMID: 29193120. doi:10.1002/lary.27009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。